Halozyme Therapeutics, Inc. (HALO)
 NASDAQ: HALO · Real-Time Price · USD
 67.92
 +1.72 (2.60%)
  Nov 4, 2025, 9:54 AM EST - Market open
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees 
 350
Change (1Y) 
 -23
Growth (1Y) 
 -6.17%
Revenue / Employee 
 $3,551,006
Profits / Employee 
 $1,701,406
Market Cap 
7.94B
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 350 | -23 | -6.17% | 
| Dec 31, 2023 | 373 | -20 | -5.09% | 
| Dec 31, 2022 | 393 | 248 | 171.03% | 
| Dec 31, 2021 | 145 | 9 | 6.62% | 
| Dec 31, 2020 | 136 | 4 | 3.03% | 
| Dec 31, 2019 | 132 | -149 | -53.02% | 
| Dec 31, 2018 | 281 | 26 | 10.20% | 
| Dec 31, 2017 | 255 | -4 | -1.54% | 
| Dec 31, 2016 | 259 | 43 | 19.91% | 
| Dec 31, 2015 | 216 | 63 | 41.18% | 
| Dec 31, 2014 | 153 | -17 | -10.00% | 
| Dec 31, 2013 | 170 | 18 | 11.84% | 
| Dec 31, 2012 | 152 | 17 | 12.59% | 
| Dec 31, 2011 | 135 | 33 | 32.35% | 
| Dec 31, 2010 | 102 | -38 | -27.14% | 
| Dec 31, 2009 | 140 | 10 | 7.69% | 
| Dec 31, 2008 | 130 | 38 | 41.30% | 
| Dec 31, 2007 | 92 | 52 | 130.00% | 
| Dec 31, 2006 | 40 | - | - | 
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
HALO News
- 13 hours ago - Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript - Seeking Alpha
 - 17 hours ago - HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS - PRNewsWire
 - 11 days ago - Halozyme Just Bought Its Next Decade Of Growth - Seeking Alpha
 - 14 days ago - Halozyme to Report Third Quarter 2025 Financial and Operating Results - PRNewsWire
 - 25 days ago - Strong And Rising: Halozyme Therapeutics Stock May Have More Upside - Forbes
 - 4 weeks ago - Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript - Seeking Alpha
 - 4 weeks ago - Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup - Reuters
 - 4 weeks ago - Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s - PRNewsWire